Leukeran (chlorambucil) / Aspen Pharma, GSK - LARVOL DELTA

A genomic analysis of patients with chronic lymphocytic leukemia treated with fixed duration therapy in a first-line setting in alberta, Canada (ASH 2025) - "For younger, fit patients with favourable-risk genetic markers such as the absence of del(17p)/ TP53 mutations and mutated IGHV, first-line (1L) chemoimmunotherapy (CIT) with fludarabine, cyclophosphamide, and rituximab (FCR) remains a reasonable option. With the emergence of targeted fixed-duration (FD) therapies, such as venetoclax plus obinutuzumab (V+O) and ibrutinib plus venetoclax (I+V), which have demonstrated superior efficacy and reduced toxicity, CIT use has declined in the 1L setting (Al-Sawaf et al., 2024; Schnaiter et al., 2024; George et al., 2025)...Among patients receiving CIT, 61 (30.5%) received FCR, 76 (38%) received bendamustine plus rituximab (BR), 26 (13%) received chlorambucil plus obinutuzumab (Clb+O), and 6 (3%) received chlorambucil plus rituximab (Clb+R)... In this chart-reviewed cohort of 200 patients, the average age at diagnosis was 65 years and 69.8% were male. 22% and 22.5% presented with Rai stage 3 or 4, respectively, at 1L therapy..."

Clinical • Genomic analysis • IO biomarker • Omic analysis • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • IGH • TP53

Efficacy and safety of obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia: A reappraisal for low-resource settings (ASH 2025) - "Despite being phased out in wealthier health systems, chlorambucil remains a relevant therapeutic option when combined with obinutuzumab—especially in regions where modern targeted therapies are unavailable. This regimen offers a viable, evidence-backed alternative for treatment-naive CLL patients in low-resource settings, with acceptable safety and efficacy profiles."

Clinical • Chronic Kidney Disease • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia

CD5-positive lymphoproliferative disorders with atypical phenotypes are associated with inferior overall survival compared to typical-phenotype chronic lymphocytic leukaemia when treated with targeted agents. (ASH 2025) - "Chemotherapy (CT) or chemoimmunotherapy (CIT) was the first line treatment in 15 (58%) and targeted treatment (TT) in 11 (42%) including bendamustine + rituximab in 6 (23%), fludarabine + cyclophosphamide + rituximab in 3 (11.5%), dexamethasone+ cyclophosphamide+ rituximab in 2 (7.7%), chlorambucil in 3 (11.5%), rituximab alone in 1 (3.8%), acalabrutinib in 6 (23%), ibrutinib in 2 (7.7%), Zanubrutinib + venetoclax (clinical trial) in1 (3.8%) and venetoclax + obinutuzumab in 2 (7.7%). Massive splenomegaly is a major feature in patients with CD5+LPD with atypical phenotype. These patients have an inferior OS outcome when treated with TT compared to CLL patients with typical phenotype."

Clinical • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Mantle Cell Lymphoma • CCND1 • CD5

The clinical trials landscape in chronic lymphocytic leukemia: A systematic review of control arm adequacy (ASH 2025) - "The Alliance A041202 and CLL14 trials demonstrated substantial progression-free survival (PFS) benefits of BTKi monotherapy and fixed-duration venetoclax plus obinutuzumab (Ven/Obi), respectively, establishing them as standard first-line treatments...Six trials (42.8%) employed substandard control arms, all utilizing a combination of chemoimmunotherapy: fludarabine/cytarabine/rituximab or bendamustine/rituximab (n=4) or chlorambucil and rituximab (n=2)...Notably, 2 of the BTKi trials utilized ibrutinib rather than next-generation BTKis, such as acalabrutinib or zanubrutinib... Of all modern phase III trials for treatment-naive CLL, nearly half did not utilize control arms that align with the current SOC in the US or EU, risking inflated estimates of the efficacy of their experimental therapies and compromising the external validity of their results. However, although the small sample size limited statistical analysis, we found that the majority of these trials were..."

Clinical • Review • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia

Efficacy of fixed-duration venetoclax-based regimens as first-line in chronic lymphocytic leukemia: A systematic review and meta-analysis of clinical trials (ASH 2025) - "Comparisons were drawn between ven-based regimens including doublets [Ven+Obinutuzumab (Obi), Ven+Ibrutinib (Ibr), Ven+Acalabrutinib (Acala)] and triplets (BTKi + Ven + Obi) and CIT comparators such as chlorambucil+Obi or fludarabine (Flu)-based combinations...Flu cyclophosphamide rituximab/bendamustine rituximab N=519, ORR, PFS 1 year, and PFS 2 years were given as 88% (CI 56-98%), 91% ( CI 86-94%), and 80% (CI 77-84%), respectively... Ven+Obi consistently showed superior PFS and ORR compared to CIT, positioning it as a frontline standard for time-limited therapy. While the Ven+Ibr combination offered similar durability, it introduced higher cardiovascular toxicity, requiring patient-specific consideration. The addition of a third agent did not yield meaningful clinical benefit in PFS but increased myelosuppression, underscoring the need for regimen personalization."

Retrospective data • Review • Atrial Fibrillation • Chronic Lymphocytic Leukemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hypertension • Leukemia • Neutropenia

First-line venetoclax-based regimens versus chemoimmunotherapy in chronic lymphocytic leukemia: A real-world analysis from the brazilian CLL registry (ASH 2025) - "Randomized trials such as CLL14 and CLL13 have demonstrated the superiority of venetoclax-obinutuzumab (VenO) over chemoimmunotherapy in both elderly and younger, fit patients...Three-year TTNT rates were: R-chlorambucil 34%, G-chlorambucil 51%, R-bendamustine 78%, FCR 67%, VenR 77%, and VenG 83%... Real-world data from this cohort allowed us to compare venetoclax-based regimens with CIT as first-line therapy for CLL, including high-risk patients. As expected, venetoclax-based regimens showed favorable results, and their use should be considered as an effective time-limited therapy, even in lower-middle-income countries. Updated analyses with longer follow-up and broader inclusion will be presented at the meeting."

Clinical • IO biomarker • Real-world • Real-world evidence • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • B2M • TP53

Very low risk for secondary malignancies with btkis in Waldenström macroglobulinemia: A retrospective real-world multicenter study. (ASH 2025) - "However, real-world data on the incidence and characteristics of SPMs in WM are scarce.The aim of our study was to evaluate, in a real-life multicenter cohort, the incidence, type, and riskfactors associated with SPMs in WM patients treated with various therapeutic strategies, includingbendamustine-rituximab (BR), dexamethasone-rituximab-cyclophosphamide (DRC), otherchemoimmunotherapy (CIT) schemes including fludarabine or chlorambucil or cladribine, BTK inhibitors(BTKis), and rituximab or steroids.This retrospective analysis included 489 patients diagnosed with WM and treated across 14 Italianhematology centers from 2008 to 2024. Although retrospective, our findings support the integration of BTKi early intreatment algorithms to reduce SPM risk. Prospective registries, longer-term follow-up and comparisonwith other casistics will be critical to define cumulative risk, especially as next-generation BTKi showpromising results with even better selectivity and tolerability."

Real-world • Real-world evidence • Retrospective data • Hematological Malignancies • Lymphoma • Lymphoplasmacytic Lymphoma • Oncology • Waldenstrom Macroglobulinemia • MYD88

First-line ibrutinib + venetoclax shows benefit across genomic subgroups in patients with chronic lymphocytic leukemia (CLL): Results from Phase 2 captivate study and Phase 3 glow study (ASH 2025) - "Here we report outcomes in subgroups by genomic alterations in patients(pts) treated with fixed-duration (FD) ibrutinib (Ibr) + venetoclax (Ven) in the phase 2 CAPTIVATE study andin those treated with FD Ibr+Ven or chlorambucil (Clb) + obinutuzumab (Obi) in the phase 3 GLOW study.The impact of the 4-gene signature (BCOR, CCND2, NRAS, and XPO1; BCNX), which was found to bepredictive of PFS and OS with MRD-guided Ibr+Ven in pts with relapsed/refractory CLL in the VISION study(Brieghel et al, ASH 2024), was also assessed in pts with previously untreated CLL who were treated withFD Ibr+Ven in the CAPTIVATE FD cohort and with MRD-guided Ibr+Ven in the CAPTIVATE MRD cohort. These robust analyses from CAPTIVATE and GLOW showed that FD Ibr+Ven provided clinicalbenefit across almost all subgroups of pts with and without genomic alterations. Ibr+Ven provided clinicalbenefit compared with Clb+Obi across all genomic subgroups in GLOW. The proposed BCNX mutationsignature had no..."

Clinical • IO biomarker • P2 data • P3 data • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • BCOR • CCND2 • IGH • IGLL5 • NOTCH1 • NRAS • PCLO • RPS15 • SF3B1 • TP53

Real-world treatment patterns and outcomes in patients with CLL and cardiovascular comorbidities: Interim analysis of the multicenter study conducted by eric. (ASH 2025) - "The most common 1L treatments were chlorambucil-based (CHL) regimens[295/857 (34.4%), CHL monotherapy: 117 (13.7%) and CHL plus anti-CD20 monoclonal antibody: 178(20.1%)] and BTK inhibitors (BTKis) [141/857 (16.5%), ibrutinib (I): 92 (10.7%), acalabrutinib (A): 45 (5.3%),zanubrutinib (Z): 4 (0.5%)]. Fludarabine-cyclophosphamide-rituximab (FCR) and bendamustine-rituximab(BR) were used in 133 (15.6%) and 53 (6.2%), respectively. Venetoclax-based (ven) regimens were used in55 [6.4%, 50 (5.8%) received ven-obinutuzumab] pts...Differences in pts age and treatment duration acrossregimens may have contributed to the varying incidence of CV tox leading to discontinuation, especially inpts receiving BTKi. The study's retrospective nature, age and f/u differences preclude any comparison ofTTNTD between treatments."

Clinical • HEOR • IO biomarker • Real-world • Real-world evidence • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Chronic Lymphocytic Leukemia • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Hematological Malignancies • Leukemia • Myocardial Infarction • Pulmonary Arterial Hypertension • IGH • TP53

Survival differences of patients with treatment-naive CLL between the chemoimmunotherapy and BTKi eras: An eric study. (ASH 2025) - "This is a retrospective, observational study that aimed to explore differences in the OS of patients with TNCLL treated a) in different eras [CIT-era group vs BTKi-era] and b) with BTKis vs fludarabine-cyclophosphamide-rituximab (FCR) in a RW setting...Cases treated in India and Serbia did not reach the 25% cut-off and were allocated to the CIT-era group.BTKis represented the most common treatment in 1L for the BTKi-era group [484 (37%), ibrutinib-based:443 (91.5%), acalabrutinib-based: 34 (7%), and zanubrutinib-based: 7 (1.5%)], while only 67 (5.1%) caseswere treated with venetoclax-based regimens, reflecting the later approval of these regimens in 1L. In theCIT-era group, FCR (1478, 34.1%) chlorambucil-based (1131, 26.2%) and bendamustine plus anti-CD20antibody (549, 12.7%) were the most common treatments...Our findings show that the availability of BTKis has improved the OS of patients with TN CLL. Patientstreated with BTKis had a similar OS with cases treated with..."

Clinical • IO biomarker • Chronic Lymphocytic Leukemia • IGH • TP53

Systematic molecular profiling to identify determinants of response to ibrutinib (ASH 2025) - P3 | "The treatment arm comprised83 patients who received ibrutinib and 39 who received chlorambucil in the RESONATE‑2 trial(NCT01722487). Multi‑omics profilingreveals mutation‑defined subclones with divergent sensitivity to targeted therapy and delineates twoinformative expression states: a high‑risk NF‑κB/inflammatory cluster (C4; poor PFS) and a clusterenriched with contracting subclones with depleted TNF-ɑ signalling via NF‑κB (C3). Integrating clonalgrowth kinetics with genomic, transcriptomic, and methylation data can potentially identify patients likelyto progress on BTK inhibitors and identify actionable pathways for adaptive or combination therapy."

IO biomarker • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • BIRC3 • ICOSLG • NFKB2 • NOTCH1 • POT1 • SF3B1 • SOCS3 • TNFAIP3 • TP53

A retrospective population-based study of long-term treatments and outcomes inwaldenstrom macroglobulinemia in Ontario, Canada (ASH 2025) - "We characterized real-world long-term outcomes in a large population-based cohort ofWaldenstrom's patients. Newly diagnosed patients over the past two decades have received multiplefrontline treatment regimens and overall have robust long-term survival outcomes."

Retrospective data • Hematological Malignancies • Lymphoma • Lymphoplasmacytic Lymphoma • Non-Hodgkin’s Lymphoma • Waldenstrom Macroglobulinemia

Clinical outcomes of first-line venetoclax-based regimens vs second-generation BTK inhibitors in CLL/SLL: A retrospective cohort study (ASH 2025) - "Patients who had received priortherapies for CLL/SLL with chlorambucil, cyclophosphamide, fludarabine, bendamustine, or ibrutinibwere excluded...Cohort 1 includedpatients treated with venetoclax-based regimens (with or without rituximab or obinutuzumab), andcohort 2 included those receiving second-generation BTKis (acalabrutinib or zanubrutinib)... Venetoclax-based regimens were associated with a less favorable safety profile and aninferior 1-year overall survival when compared to second-generation BTKis-based treatments as first lineof therapy in patients with CLL/SLL. To inform clinical decision-making and optimize patient outcomes,future studies should include randomized controlled trials with comprehensive clinical data andextended follow-up durations."

Clinical data • Retrospective data • Atrial Fibrillation • Cardiomyopathy • Chronic Kidney Disease • Chronic Lymphocytic Leukemia • Congestive Heart Failure • Diabetes • Febrile Neutropenia • Heart Failure • Hematological Disorders • Hematological Malignancies • Hypertension • Infectious Disease • Leukemia • Metabolic Disorders • Nephrology • Neutropenia • Pneumonia • Renal Disease • Respiratory Diseases • Septic Shock • Small Lymphocytic Lymphoma

Real-world selection of fixed-duration versus continuous therapies for treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (ASH 2025) - "Continuous treatment with BTK inhibitors (BTKi) and fixed-duration (FD) regimens such asvenetoclax-obinutuzumab (Ven-O) or ibrutinib-venetoclax (I+V) are now standard options...I+V was available in select cases via special access request or private insurance.Legacy chemoimmunotherapy regimens—including fludarabine, cyclophosphamide, and rituximab (FCR); bendamustine-rituximab (BR); and chlorambucil-obinutuzumab (Chl-O)—remained publicly funded for TNCLL/SLL...Targeted FD therapies were selected for 75 (51%) patients, including Ven-O (n=73, 49%) and I+V (n=2, 1%).Continuous BTKi therapy was administered to 65 (44%) patients, including zanubrutinib (n=39, 26%),acalabrutinib (n=25, 17%), and ibrutinib (n=1, 1%)... This real-world, population-based study reveals that FD and continuous targeted therapiesare selected with similar frequency as first-line treatments for CLL/SLL. Treatment selection is primarilyinfluenced by age, presence of del(17p)/TP53 mutations, patient..."

Clinical • IO biomarker • Real-world • Real-world evidence • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Small Lymphocytic Lymphoma • IGH • TP53

A decade of progress: A comparative analysis of real-world survival in chronic lymphocytic leukemia across therapeutic eras (ASH 2025) - "The ECOG E1912 randomized study demonstratedsuperior overall survival of ibrutinib-based therapy compared to chemoimmunotherapy with fludarabine,cyclophosphamide, and rituximab (FCR)...For these cohorts, 5-year all-cause mortality was comparedbetween the pre-2015 and 2015-2020 groups, and 2-year all-cause mortality was compared between thepre-2015 and post-2020 groups.Second, to directly compare treatment effectiveness, patients who received systemic therapy werestratified into two cohorts based on the class of agent received, irrespective of the treatment date:Chemoimmunotherapy (CIT): Regimens including FCR, BR, Fludarabine with Rituximab,Chlorambucil ± Obinutuzumab, and Alemtuzumab-based treatments.Novel Targeted Therapy: Regimens including covalent BTK inhibitors (Ibrutinib, Acalabrutinib,Zanubrutinib), BCL-2 inhibitor Venetoclax (± Rituximab or Obinutuzumab), and PI3K inhibitors(Idelalisib, Duvelisib).For these treatment-regimen cohorts, 10-year outcomes..."

Clinical • Real-world • Real-world evidence • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia

FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis (ASH 2025) - "Mostcommon 1L IC regimens were R-CVP (46%), R-CHOP-like (32%), R-chlorambucil (9%), and B-R (9%).FLIPI24 stratified patients into low- (18%), intermediate- (37%), and high-risk (45%) groups. ConclusionFLIPI24 demonstrates strong and consistent prognostic performance across all MZL subtypes, identifying~40% of patients as high-risk with significantly worse survival and increased lymphoma-related mortality.The FLIPI24 outperforms FLIPI, MZL-IPI, IPI, and MALT-IPI in predicting outcomes and may serve as apractical tool to guide risk-adapted management and selection of patients for novel therapies in MZL. Funding: NU21-03-00411, P50 CA97274, U01 CA195568."

Follicular Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • B2M • CA724 • CA9

Dissecting the heterogeneity of IGHV-mutated CLL: An eric study. (ASH 2025) - "FCR was the most common 1L treatment (395, 20.8%) followed by chlorambucil (Chl)monotherapy (320, 16.9%). BTK inhibitors (BTKis) were used in 241 cases [12.5%; ibrutinib: 162 (8.3%),acalabrutinib 65 (3.4%), zanubrutinib: 10 (0.5%), pirtobrutinib 4 (0.2%)]. BR, Chl-rituximab and Chl-obinutuzumab were used in 185 (9.8%), 126 (6.6%) and 98 (5.2%) cases, respectively. Finally, 70 (3.6%)received venetoclax-obinutuzumab 1L treatment and 33 (1.7%) received ibrutinib-venetoclax...Older age, CK5 and TP53 aberrations are independent high-risk factors for shorter OS in M-CLL.Utilization of IGHV2 subgroup genes emerged as adverse-prognostic for OS and merits furtherevaluation."

Heterogeneity • Chronic Lymphocytic Leukemia • IGH • TP53

Redefining early vs late progressive disease (PD) in chronic lymphocytic leukemia: A pooled analysis of fixed-duration therapies (ASH 2025) - "2,921 pts (76.3%) were treated with CIT (bendamustine + rituximab(R), fludarabine +/- cyclophosphamide +/- R; chlorambucil, chlorambucil + R or + obinutuzumab (O)) and908 with TT (23.7%) (venetoclax + O, venetoclax + R, venetoclax + O + ibrutinib). This analysis challenges the current definition of early vs. late PD commonly used in CLLtreatment guidelines in the context of targeted fixed-duration therapy. Pts who experience PD within 12months after stopping treatment have a significantly higher risk of death, independent of TP53aberrations and IGHV mutational status, highlighting the high-risk nature of early PD."

Retrospective data • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • IGH • TP53

Frontline therapy patterns and outcomes in chronic lymphocytic leukemia: A real-world, multicenter analysis from Latin America. (ASH 2025) - "We grouped treatment regimens into six categories: a) venetoclax-based combinations with or without anti-CD20 antibodies; b) Bruton tyrosine kinase (BTK) inhibitors; c)standard CIT, including fludarabine, cyclophosphamide, and rituximab (FCR), or bendamustine andrituximab (BR); d) fludarabine and cyclophosphamide without rituximab (FC); e) rituximab orobinutuzumab combined with chlorambucil (R/G-chlorambucil); and f) suboptimal regimens, includingchlorambucil monotherapy, R-CHOP, R-CVP, or any other nonstandard or unsupported combinations.Patients with less than 3 months of follow-up were excluded. This real-world analysis reinforces the urgent need to abandon the use of non-CLL-directed regimenssuch as CHOP or CVP as well as chlorambucil monotherapy in the treatment of patients with CLL. Addinganti-CD20 antibodies significantly improved outcomes for FC-based regimens. Notably, FCR and targetedagents (venetoclax or BTK inhibitors) demonstrated similar efficacy in this..."

Clinical • IO biomarker • Real-world • Real-world evidence • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • TP53

MODULE 2: Novel Strategies Combining Bruton Tyrosine Kinase (BTK) and Bcl-2 Inhibitors in CLL (ASH 2023) - "Supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, and Lilly. Mechanistic rationale for combining BTK and Bcl-2 inhibitors with or without anti-CD20 antibodies in the management of CLL Long-term efficacy and safety outcomes from early-phase studies evaluating ibrutinib in combination with venetoclax for patients with treatment-naïve and relapsed/refractory (R/R) CLL Design, eligibility criteria and major findings from the Phase III GLOW trial evaluating ibrutinib/venetoclax versus chlorambucil/obinutuzumab as first-line therapy for older/unfit patients with CLL Published outcomes from other Phase III trials, such as FLAIR and GAIA (CLL13) exploring the use of ibrutinib and venetoclax in combination Available data sets evaluating acalabrutinib and zanubrutinib in combination with venetoclax with or without an anti-CD20 antibody Ongoing Phase III efforts assessing novel doublet and triplet combinations for CLL"

Chronic Lymphocytic Leukemia

Population-Based Registry Data over 15 Years Suggests Comparable Overall Survival for CLL Patients Treated with Chemoimmunotherapy and Targeted Therapies As First-Line Treatments (ASH 2024) - "The first-line treatments with CT included chlorambucil (Chl) 60.8%, fludarabine ± cyclophosphamide (FC) 32.6%, and bendamustine (Ben) 6.6%. CIT included FC/FCM (mitoxantrone) with a CD20 antibody (ab) 52.1%, Ben with a CD20 ab 16.6%, Chl with a CD20 ab 27.2%, alemtuzumab ± CT 2.0%, and other regimens 4.0%. TT included acalabrutinib ± Obinutuzumab (O) 29.7%, ibrutinib ± rituximab (R) 36.4%, venetoclax ± O or ibrutinib 26.1%, idelalisib ± R 3.6%, and zanubrutinib 3.6%...In this population-based registry study, it was shown that only around a third of patients with CLL required treatment, and there was no OS advantage from initiating patients on targeted therapy as a first line compared to chemoimmunotherapy followed by targeted therapy upon relapse. This concept should be validated in prospective trials."

Clinical • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

Chronic lymphocytic leukemia in routine care in Germany: Changes in standard of care – results from the prospective RUBIN registry (DGHO 2025) - P | "Chemoimmunotherapy (CIT) regimens (rituximab(R)-bendamustine (53.4%), FCR (25.2%) and R-chlorambucil (6.1%)) were by far the most common between 2009 and 2015. In contrast, since 2023, obinutuzumab(O)-venetoclax (31.6%) was the most frequent regimen, followed by the 2nd generation BTKis acalabrutinib (16%) and zanubrutinib (15.5%).Of 516 prospectively documented 2L treatments, 122 (23.6%) started between 2009 and 2013, 98 (19.0%) between 2014 and 2018, and 296 (57.4%) between 2019 and 2024.Change from CIT towards targeted agents was also observed in 2L. R-bendamustine (40.8%) was still the most common regimen 2014 - 2018, followed by ibrutinib (17.3%) and R-idelalisib (8.2%)... The data from RUBIN show that after their approval, novel agents for CLL treatment are rapidly adopted into real-world practice. Current treatment guidelines are reflected, with venetoclax based regimen and 2nd generation BTKis as most frequent regimens. Outcome data over time will also be..."

Clinical • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma

Omission of Anti-CD20 Antibody in Chronic Lymphocytic Leukemia during COVID-19 Pandemic: Twelve Month Course of Venetoclax Is a Safe and Effective Alternative Regimen (ASH 2023) - "These treatments included: Chlorambucil-Obinutuzumab, Ibrutinib, Fludarabine-Cyclophosphamide-Rituximab, and Bendamustine-Rituximab...This patient then received the combination of Obinutuzumab-Acalabrutinib and achieved complete remission...The avoidance of the anti-CD 20 antibody resulted in preservation of the immunity as noted in the one patient who contracted COVID-19 during treatment but recovered quickly from infection without any COVID-19 associated complication. We believe that although Rituximab with Venetoclax remains the standard of care in advanced stage CLL, but in unusual circumstances such as during the COVID-19 pandemic, short, limited course of single agent Venetoclax is a viable option of treatment to achieve durable remission."

Anemia • Aplastic Anemia • Autoimmune Hemolytic Anemia • Chronic Lymphocytic Leukemia • Fatigue • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Neutropenia • Oncology • Thrombocytopenia • TP53

Analysis of Ventricular Arrhythmias and Sudden Death with Acalabrutinib from 5 Prospective Clinical Trials (ASH 2023) - " Incidence and relative risk of nonfatal and fatal VAs and SDs were analyzed using pooled data from 5 prospective acalabrutinib clinical trials (nonrandomized trials: CL-001 [acalabrutinib monotherapy], CL-003 [acalabrutinib + obinutuzumab]; randomized trials: CL‑006 [acalabrutinib vs ibrutinib], CL-007 [acalabrutinib ± obinutuzumab vs chlorambucil + obinutuzumab], CL-309 [acalabrutinib vs idelalisib + rituximab OR bendamustine + rituximab]). This pooled analysis of prospective acalabrutinib clinical trials demonstrates that the risk of VA and SD with acalabrutinib is low and similar to that of standard-of-care therapies when adjusted for exposure. The current analysis with more than 1200 patients treated with acalabrutinib points to favorable safety outcomes and no specific trend with SDs and VAs. Additional analyses with larger cohorts from the clinical development program and all postmarketing sources will continue to further characterize the safety profile of..."

Clinical • Atrial Fibrillation • Cardiovascular • Chronic Lymphocytic Leukemia • Hematological Malignancies • Hypertension • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study (ASH 2023) - P3 | "With prolonged follow-up of 55 months in the GLOW study, all-oral, once-daily, fixed-duration Ibr+Ven continues to show superior PFS versus Clb+O. Among patients treated with Ibr+Ven, benefit in PFS was particularly observed in patients with uIGHV who achieved uMRD at EOT+3 and in patients with mIGHV regardless of MRD status at EOT+3. Moreover, Ibr+Ven fixed-duration combination treatment continues to demonstrate an OS advantage versus chemoimmunotherapy in patients with previously untreated CLL."

Clinical • IO biomarker • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • IGH • TP53